- Home
- ZBAI vs BIVI Comparison
ZBAI vs BIVI Comparison
Compare ZBAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- BIVI
- Stock Information
- Founded
- ZBAI 2015
- BIVI 2013
- Country
- ZBAI United States
- BIVI United States
- Employees
- ZBAI N/A
- BIVI N/A
- Industry
- ZBAI Professional Services
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- BIVI Health Care
- Exchange
- ZBAI Nasdaq
- BIVI Nasdaq
- Market Cap
- ZBAI 17.3M
- BIVI 18.6M
- IPO Year
- ZBAI N/A
- BIVI N/A
- Fundamental
- Price
- ZBAI $0.32
- BIVI $1.02
- Analyst Decision
- ZBAI
- BIVI Strong Buy
- Analyst Count
- ZBAI 0
- BIVI 1
- Target Price
- ZBAI N/A
- BIVI $30.00
- AVG Volume (30 Days)
- ZBAI 2.4M
- BIVI 194.8K
- Earning Date
- ZBAI 06-06-2025
- BIVI 05-12-2025
- Dividend Yield
- ZBAI N/A
- BIVI N/A
- EPS Growth
- ZBAI N/A
- BIVI N/A
- EPS
- ZBAI N/A
- BIVI N/A
- Revenue
- ZBAI $720,000.00
- BIVI N/A
- Revenue This Year
- ZBAI N/A
- BIVI N/A
- Revenue Next Year
- ZBAI N/A
- BIVI N/A
- P/E Ratio
- ZBAI N/A
- BIVI N/A
- Revenue Growth
- ZBAI 44.00
- BIVI N/A
- 52 Week Low
- ZBAI $0.27
- BIVI $0.62
- 52 Week High
- ZBAI $2.50
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- BIVI 47.95
- Support Level
- ZBAI N/A
- BIVI $1.00
- Resistance Level
- ZBAI N/A
- BIVI $1.09
- Average True Range (ATR)
- ZBAI 0.00
- BIVI 0.07
- MACD
- ZBAI 0.00
- BIVI -0.01
- Stochastic Oscillator
- ZBAI 0.00
- BIVI 19.05
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.